These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26673009)

  • 21. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular RNA circ-CCAC1 Facilitates Adrenocortical Carcinoma Cell Proliferation, Migration, and Invasion through Regulating the miR-514a-5p/C22orf46 Axis.
    Li W; Liu R; Wei D; Zhang W; Zhang H; Huang W; Hao L
    Biomed Res Int; 2020; 2020():3501451. PubMed ID: 33195693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
    Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
    Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.
    Lin CW; Chang YH; Pu HF
    Toxicology; 2012 Aug; 298(1-3):14-23. PubMed ID: 22546480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
    Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
    Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.
    De Martino MC; van Koetsveld PM; Feelders RA; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
    Endocrine; 2016 Jun; 52(3):664-7. PubMed ID: 26645813
    [No Abstract]   [Full Text] [Related]  

  • 30. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
    Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
    PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.
    Kim HS; Yoon G; Ryu JY; Cho YJ; Choi JJ; Lee YY; Kim TJ; Choi CH; Song SY; Kim BG; Bae DS; Lee JW
    Oncotarget; 2015 Sep; 6(29):26746-56. PubMed ID: 26311741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
    Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
    Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
    Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
    Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
    Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.